Publications by authors named "Mirjam Huizenga"

Monoacylglycerol lipase (MAGL) is the pivotal catabolic enzyme responsible for signal termination in the endocannabinoid system. Inhibition of MAGL offers unique advantages over the direct activation of cannabinoid receptors in treating cancer, metabolic disorders, and inflammatory diseases. Although specific fluorescent molecular imaging probes are commonly used for the real-time analysis of the localization and distribution of drug targets in cells, they are almost invariably composed of a linker connecting the pharmacophore with a large fluorophore.

View Article and Find Full Text PDF

Monoacylglycerol lipase (MAGL) is a key enzyme for signal termination in the endocannabinoid system (ECS). MAGL inhibition results in indirect activation of the cannabinoid receptors, which offers unique advantages for the treatment of, e.g.

View Article and Find Full Text PDF

Monoacylglycerol lipase (MAGL) is the key enzyme for the hydrolysis of endocannabinoid 2-arachidonoylglycerol (2-AG). The central role of MAGL in the metabolism of 2-AG makes it an attractive therapeutic target for a variety of disorders, including inflammation-induced tissue injury, pain, multiple sclerosis, and cancer. Previously, we reported , an aryl sulfoxide, as a peripherally restricted, covalent reversible MAGL inhibitor that reduced neuropathic pain and inflammation in preclinical models.

View Article and Find Full Text PDF
Article Synopsis
  • * LEI-515 is a new MAGL inhibitor that only affects peripheral organs, increasing 2-AG levels without impacting the mouse brain, which could limit side effects.
  • * In animal studies, LEI-515 reduced liver damage and pain from chemotherapy without the negative effects seen with other MAGL inhibitors, suggesting it could be a safer option for treating inflammation and pain.
View Article and Find Full Text PDF